[Ribo Newsroom] Ribo Appoints CMO and CBO to Empower Global R&D and Partnerships

[Our Products News] Ribo expands beyond the liver with RiboPepSTAR��� ��� enabling targeted siRNA delivery to multiple organs

[Our Products News] Ribo to present ex-hepatic delivery data at RNA Leaders Europe Conference

[Our Products News] Ribo's PCSK9-targeting siRNA drug RBD7022 is about to launch Phase III clinical trials in China.

[Ribo Newsroom] Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

[Our Products News] Recent advances in factor XI (FXI) inhibition are reshaping the landscape of anticoagulation therapy

[Our Products News] Ribo Receives Phase II Clinical Approval for ApoC3-targeting siRNA drug RBD5044 in China

[Ribo Newsroom] Ribo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock Exchange